• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

No anti-fibrotic effect of selonsertib in NASH.

作者信息

Dickson Iain

机构信息

Nature Reviews Gastroenterology & Hepatology, .

出版信息

Nat Rev Gastroenterol Hepatol. 2020 May;17(5):260. doi: 10.1038/s41575-020-0297-5.

DOI:10.1038/s41575-020-0297-5
PMID:32235911
Abstract
摘要

相似文献

1
No anti-fibrotic effect of selonsertib in NASH.塞洛西布在非酒精性脂肪性肝炎中无抗纤维化作用。
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):260. doi: 10.1038/s41575-020-0297-5.
2
Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/ MAPK Pathway of Hepatic Stellate Cells.塞洛西布通过下调肝星状细胞的ASK1/MAPK信号通路抑制肝纤维化。
Biomol Ther (Seoul). 2020 Nov 1;28(6):527-536. doi: 10.4062/biomolther.2020.016.
3
Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis.用于治疗非酒精性脂肪性肝炎的3期药物研发进程
Hepatol Res. 2019 Nov;49(11):1256-1262. doi: 10.1111/hepr.13425. Epub 2019 Oct 25.
4
Effects of Selonsertib in Patients with Diabetic Kidney Disease.Selonsertib 治疗糖尿病肾病患者的效果。
J Am Soc Nephrol. 2019 Oct;30(10):1980-1990. doi: 10.1681/ASN.2018121231. Epub 2019 Sep 10.
5
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.ASK1 抑制剂 selonsertib 治疗非酒精性脂肪性肝炎患者的随机、2 期临床试验。
Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26.
6
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.非酒精性脂肪性肝炎患者的 MRE、MRI-PDFF 与肝组织学的纵向相关性：selonsertib 二期临床试验数据分析。
J Hepatol. 2019 Jan;70(1):133-141. doi: 10.1016/j.jhep.2018.09.024. Epub 2018 Oct 4.
7
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.塞尔尼索特治疗非酒精性脂肪性肝炎的肝纤维化改善和患者报告结局。
Liver Int. 2018 Oct;38(10):1849-1859. doi: 10.1111/liv.13706. Epub 2018 Feb 22.
8
Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1-JNK-DRP1 pathway.塞洛西布，一种通过ASK1-JNK-DRP1途径挽救巨噬细胞线粒体功能障碍来治疗肝衰竭的潜在药物。
Cell Biosci. 2021 Jan 7;11(1):9. doi: 10.1186/s13578-020-00525-w.
9
MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.MACK-3（hoMa、Ast 和 CK18 的组合）：纤维化非酒精性脂肪性肝炎有前途的新型生物标志物。
Liver Int. 2019 Jul;39(7):1315-1324. doi: 10.1111/liv.14084. Epub 2019 Mar 18.
10
sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH.可溶性鸟苷酸环化酶刺激剂普拉西古肽可抑制 NASH 模型中的星状细胞纤维化转化，并抑制纤维化和炎症。
Proc Natl Acad Sci U S A. 2019 May 28;116(22):11057-11062. doi: 10.1073/pnas.1821045116. Epub 2019 May 13.

引用本文的文献

1
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies.非酒精性脂肪性肝病（NAFLD）、2型糖尿病与非病毒性肝癌：病理生理机制及新治疗策略
Biomedicines. 2023 Feb 6;11(2):468. doi: 10.3390/biomedicines11020468.
2
Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency.肝脏蛋白质组的过度磷酸化是S-腺苷甲硫氨酸缺乏所致非酒精性脂肪性肝病的特征。
iScience. 2023 Jan 14;26(2):105987. doi: 10.1016/j.isci.2023.105987. eCollection 2023 Feb 17.
3
Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing.

本文引用的文献

1
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.基于 III 期 STELLAR 临床试验结果：塞利昔布治疗 NASH 相关桥接纤维化或代偿期肝硬化患者。
J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.
探究塞洛西布抑制细胞周期蛋白依赖性激酶6抑制潜能的机制：药物重新利用的新见解
Front Oncol. 2022 May 26;12:865454. doi: 10.3389/fonc.2022.865454. eCollection 2022.
4
Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).预测非酒精性脂肪性肝病（NAFLD）进展的因素。
Cureus. 2021 Dec 28;13(12):e20776. doi: 10.7759/cureus.20776. eCollection 2021 Dec.
5
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives.非酒精性脂肪性肝炎/非酒精性脂肪肝病的靶向治疗：从分子层面到药物及手术治疗选择
J Pers Med. 2021 Jun 2;11(6):499. doi: 10.3390/jpm11060499.
6
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.2 型糖尿病和肥胖症患者肝衰竭的代谢谱：从非酒精性脂肪性肝病到非酒精性脂肪性肝炎再到肝细胞癌。
Int J Mol Sci. 2021 Apr 26;22(9):4495. doi: 10.3390/ijms22094495.
7
FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.成纤维细胞生长因子19和21用于非酒精性脂肪性肝炎的治疗——同一枚硬币的两面？从小鼠到人类，成纤维细胞生长因子19和21的差异与重叠效应
Front Endocrinol (Lausanne). 2020 Dec 22;11:601349. doi: 10.3389/fendo.2020.601349. eCollection 2020.